Table 1.

CAR T cells trials in CLL. Abbreviation: ORR—overall response rate, CR—complete response, CLL—chronic lymphocytic leukemia.

Study (Reff. Number)	Number of CLL Patients	Target Antigen	Costimulatory Domain	ORR (%)	CR (%)
CAR-T
[23]	8	CD19	CD28	0	0
[27]	3	CD19	4–1BB	100	67
[28]	4	CD19	CD28	75	25
[24]	4	CD19	CD28	25	0
[29]	5	CD19	CD28	100	60
[30]	14	CD19	4–1BB	57	29
[25]	5	CD19	CD28	40	20
[26]	2	IgKappa	CD28	0	0
[31]	32	CD19	4–1BB	44	28
[13]	24	CD19	4–1BB	71	17
[22]	8	CD19	CD28	75	25
[32]	19	CD19	4–1BB	53	53
[33]	10	CD19	4–1BB	60	40
[34]	19	CD19	4–1BB	79	21
[35]	3	CD19	4–1BB	100	67